At the turn of the year, GSK Stockmann is welcoming Daniel Fehling to strengthen its Corporate/M&A practice in Hamburg
Daniel Fehling (43) will be joining GSK Stockmann’s Hamburg team as an equity partner on 1 January 2024. He has been practising as a lawyer for 13 years and will be joining GSK Stockmann from Luther, where he has been working – recent years as a partner – in the corporate/M&A department for over ten years. Fehling advises (family-owned) businesses, family offices and private equity investors on (cross-border) transactions (M&A, private equity). Daniel Fehling will thus be working closely with GSK Stockmann’s offices in London and Luxembourg. He also advises in all corporate law matters, including restructurings. Fehling is a certified specialist for commercial and corporate law as well as for banking and capital markets law. He holds a Master of Laws (LL.M.) from the University of Auckland, New Zealand.
GSK Stockmann focuses on advising on complex and cross-border transactions structured via Luxembourg and London in the areas of private equity, venture capital and real estate. The firm has taken important steps on this path in recent years with the opening of an office in Luxembourg in 2016 and a representative office in London in 2022.
“Thanks to his M&A expertise, Daniel Fehling will help us to further expand the range of advisory services we offer in this area at an international level,” comments Managing Partner Oliver Glück on the new hire. “The continuous growth of our corporate/M&A practice is a reflection of our long-term international strategy.” In the fourth quarter of 2023, GSK Stockmann brought two specialists in the area of corporate/M&A on board, Anna Gassner in Luxembourg and Robert Korndörfer in Berlin.
